E
CSBR icon

Ergoteles’s Champions Oncology CSBR Stock Holding History

Ergoteles’s Portfolio CSBR Stock Details CSBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,937
Closed -$105K – 1525
2022
Q3 		$105K Buy
+13,937
New +$117K ﹤0.01% 1362
2021
Q4 		– Sell
-30,565
Closed -$312K – 1298
2021
Q3 		$312K Sell
30,565
-335
-1% -$3.41K 0.01% 781
2021
Q2 		$318K Buy
+30,900
New +$313K 0.01% 1040

Other funds holding CSBR

BMC
Battery Management Corp Boston, Massachusetts $426M AUM 21.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
MAG
Millrace Asset Group Berwyn, Pennsylvania $98.4M AUM 63.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's CSBR Position: Q4 2022 in Review

Ergoteles sold out of Champions Oncology (CSBR) in Q4 2022, closing a stake of 13,937 shares — an estimated $105K sold.

Ergoteles first reported a position in CSBR in Q2 2021 and held it in 3 quarters. The position peaked at $318K in Q2 2021. 29 funds tracked by Wall St. Rank hold CSBR as of Q4 2022.

  • Ergoteles reported no remaining Champions Oncology position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 13,937 Champions Oncology shares in Q4 2022, an estimated $105K.
  • Ergoteles first reported a position in Champions Oncology in Q2 2021 and held it in 3 quarters.
  • Ergoteles's Champions Oncology position peaked at $318K in Q2 2021.
  • 29 funds tracked by Wall St. Rank held Champions Oncology as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.